Product category:
Microplate readers
News Release from: BioTek Instruments | Subject: Synergy 2
Edited by the Laboratorytalk Editorial
Team on 07 April 2008
Synergy selected for FP-based diagnostic
kits
BioTek's Synergy 2 multi-mode microplate reader will be distributed by Diachemix primarily for use with its Brucellosis and M bovis assay kits
These assay kits use fluorescence polarisation (FP) technology to rapidly, consistently and accurately detect the presence of the aforementioned pathogens in animal samples According to Michael Jolley, Diachemix scientific director and founder, and developer of the first commercial FP assays: "The Synergy 2 is overall the best FP microplate instrument that we have evaluated for the reading of our assays for detection of antibodies to Brucella abortus, the causative agent of brucellosis, and Mycobacterium bovis, the causative agent of bovine TB
This article was originally published on Laboratorytalk on 19 Jun 2006 at 8.00am (UK)
Related stories
Microplate reader has multiple detection modes
Based on the popular Synergy HT, the Synergy 2 is a five-mode microplate reader designed for the life science research and drug discovery markets
"Not only that, it is the lowest cost instrument on the market.
"We are confident that our customers will be very pleased with the performance of the combination of our assays and the Synergy 2".
"The Synergy 2 exceeded our expectations by performing at a higher level, faster, and with far superior user-friendliness than any instrument we have ever utilised," added Donald Combs, Diachemix chief operating officer.
"We are certain that our customers will be very happy with the value of the instrument and its capabilities".
In addition to FP, the Synergy 2 can be equipped with fluorescence intensity, time-resolved fluorescence, luminescence and monochromator-based absorbance detection systems.
• BioTek Instruments: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page

